Section: Microbiology

Original Research Article

MODERN MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASES: ADVANCES IN DIAGNOSTICS, ANTIMICROBIAL RESISTANCE, SURVEILLANCE, AND EMERGING TECHNOLOGIES

J. Suriakumar[1], B.S.Sangeetha[2], T. Murugalakshmi[3], R. Gopinathan[4], S.Kovendan[5], J.Srisaravanan[6]

[1]Associate Professor, Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India
[2]Professor, Department of Pathology, Chettinad Hospital and Research Institute, Chettinad Academy of Research & Education, Kelambakkam, Tamil Nadu, India.
[3]Assistant Professor, Department of Pharmacology, Government Medical College, Dindigul, Tamil Nadu, India.
[4]Assistant Professor, Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India.
[5]Assistant Professor, Department of Microbiology, Government Dindigul Medical College, Tamil Nadu, India.
[6]Dean, Government Medical College, Dindigul, Tamil Nadu, India.

Received : 02/10/2026
Received in revised form : 29/10/2026
Accepted : 12/11/2026

Keywords:
Medical microbiology; infectious diseases; antimicrobial resistance; molecular diagnostics; antimicrobial stewardship.

Corresponding Author:
Dr. J. Suriakumar,
Email: suryjay@gmail.com

DOI: 10.47009/jamp.2026.8.6.17

Source of Support: Nil,
Conflict of Interest: None declared

Int J Acad Med Pharm
2026; 8 (6); 93-109

ABSTRACT

Background: Medical microbiology plays a central role in understanding, diagnosing, preventing, and managing infectious diseases caused by bacteria, viruses, fungi, and parasites. Despite advances in antimicrobial therapy, vaccination, molecular diagnostics, and infection-control practices, infectious diseases remain a major global health challenge. The emergence of antimicrobial resistance, novel pathogens, and re-emerging infections further emphasizes the need for improved diagnostic, therapeutic, and surveillance strategies. Recent developments in genomics, metagenomic sequencing, artificial intelligence, biosensors, and point-of-care technologies are transforming clinical microbiology and infectious disease management. **Materials and Methods:** This narrative review examines contemporary developments in medical microbiology and infectious disease research. Relevant scientific literature, review articles, clinical guidelines, and reports from recognized national and international health organizations were considered. The review focuses on microbial pathogenicity, host–pathogen interactions, conventional and advanced diagnostic methods, antimicrobial resistance mechanisms, emerging and re-emerging infectious diseases, infection prevention and control, and microbiological surveillance. Particular attention was given to recent advances in molecular diagnostics, genomic epidemiology, artificial intelligence, and antimicrobial stewardship. **Results:** Advances in molecular techniques, including polymerase chain reaction, real-time PCR, next-generation sequencing, and metagenomic sequencing, have improved the speed, sensitivity, and accuracy of pathogen identification. Increasing antimicrobial resistance among clinically important microorganisms highlights the importance of antimicrobial susceptibility testing, molecular resistance detection, and appropriate antimicrobial stewardship practices. Artificial intelligence, automated diagnostic platforms, biosensors, and point-of-care testing offer promising opportunities for rapid diagnosis, disease prediction, and improved clinical decision-making. Furthermore, integrated laboratory surveillance, genomic epidemiology, and infection prevention strategies are essential for the early detection and containment of emerging infectious threats. **Conclusion:** Medical microbiology continues to evolve through the integration of conventional microbiological methods with advanced molecular technologies, genomics, bioinformatics, and artificial intelligence. Strengthening diagnostic capacity, antimicrobial stewardship, infection prevention and control, and integrated surveillance systems is essential to address antimicrobial resistance and emerging infectious diseases. Multidisciplinary collaboration between microbiologists, clinicians,

researchers, and public health professionals will be crucial for improving patient outcomes and strengthening global health preparedness.
Keywords: Medical microbiology, Infectious Diseases, Antimicrobial Resistance, Molecular Diagnostics, Antimicrobial Stewardship.

INTRODUCTION

Infectious diseases remain a major global health challenge and continue to cause substantial morbidity and mortality despite advances in sanitation, vaccination, antimicrobial therapy, and diagnostic technologies. They are caused by diverse microorganisms, including bacteria, viruses, fungi, protozoa, and helminths, and may range from localized infections to severe systemic diseases.[1] Their distribution and impact are influenced by environmental changes, population growth, urbanization, healthcare access, sanitation, travel, and host susceptibility. Medical microbiology plays a central role in understanding, diagnosing, treating, and preventing infectious diseases.[2] It encompasses the identification and characterization of pathogenic microorganisms, investigation of microbial virulence and host-pathogen interactions, antimicrobial susceptibility testing, epidemiological surveillance, and development of diagnostic and preventive strategies.[3] Clinical microbiology laboratories therefore provide essential information for clinical decision-making, infection control, and public health surveillance. Bacteria, viruses, fungi, and parasites are responsible for a broad spectrum of human infections.[4] Bacterial pathogens such as Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Mycobacterium tuberculosis cause respiratory, urinary, gastrointestinal, bloodstream, wound, and other infections.[5] Viral diseases, including respiratory viral infections, hepatitis, dengue, human immunodeficiency virus infection, and emerging viral diseases, represent another major component of the global infectious disease burden.[6,7] Invasive fungal infections caused by Candida, Aspergillus, and Cryptococcus species are particularly important among immunocompromised and critically ill patients, while parasitic diseases such as malaria and other neglected tropical infections remain significant public health problems.[8,9]

The outcome of infection depends on complex interactions between microbial virulence factors and host immune responses. Microbial structures such as adhesins, pili, fimbriae, flagella, capsules, and surface proteins facilitate attachment and colonization, while toxins, immune-evasion mechanisms, intracellular survival, and biofilm formation contribute to persistence and disease severity.[10] Understanding these interactions is essential for developing effective diagnostic, therapeutic, and preventive approaches. Laboratory diagnosis is fundamental to the appropriate management of infectious diseases. Conventional methods, including microscopy, staining, culture, biochemical identification, antigen detection, and antimicrobial susceptibility testing, remain widely used. However, these approaches may be time-consuming or have limited sensitivity for certain pathogens. Molecular techniques such as polymerase chain reaction (PCR), real-time PCR, reverse-transcription PCR, and multiplex assays have significantly improved the speed and accuracy of pathogen detection.[11,12] More recently, next-generation sequencing, whole-genome sequencing, and metagenomic approaches have expanded the capacity to identify pathogens, investigate transmission, and characterize antimicrobial resistance.[13] Antimicrobial resistance (AMR) is one of the most important threats to effective infectious disease treatment. Excessive and inappropriate antimicrobial use, inadequate infection-control practices, and environmental dissemination of resistant organisms contribute to the emergence and spread of resistance. Mechanisms include antimicrobial inactivation, alteration of drug targets, reduced permeability, and active efflux. Multidrug-resistant organisms, including methicillin-resistant S. aureus, extended-spectrum β-lactamase-producing Enterobacterales, and carbapenem-resistant Gram-negative bacteria, increasingly complicate clinical management.[14,15] Antimicrobial susceptibility testing, surveillance, antimicrobial stewardship, and development of alternative therapies are therefore essential for controlling AMR. Emerging and re-emerging infectious diseases further complicate global health preparedness. Climate change, ecological disturbances, urbanization, international travel, population movement, and increased human-animal interactions can influence the emergence and transmission of infectious agents. Vector-borne diseases such as dengue, malaria, chikungunya, and Japanese encephalitis remain important in endemic regions, while zoonotic infections continue to present new threats.[16,17] These challenges highlight the importance of integrated surveillance and the One Health approach, which recognizes the interconnection between human, animal, and environmental health.

The COVID-19 pandemic demonstrated the potential of emerging pathogens to rapidly affect healthcare systems and societies worldwide. It emphasized the importance of laboratory preparedness, rapid molecular diagnostics, genomic surveillance, infection prevention and control, vaccination, and coordinated public health responses. Recent advances in point-of-care testing, biosensors, microfluidics, isothermal amplification, CRISPR-based detection, and artificial intelligence are creating new opportunities for rapid and accessible pathogen detection, particularly in resource-limited settings.[18,19]

ISSN (O): 2687-5365; ISSN (P): 2753-6556



Figure 1: Integrated framework of modern medical microbiology and infectious disease management.

Modern medical microbiology is therefore evolving from conventional pathogen identification toward an integrated discipline combining microbiology, molecular biology, genomics, bioinformatics, advanced diagnostics, antimicrobial stewardship, and public health surveillance. This review summarizes major developments in medical microbiology and infectious diseases, with emphasis on microbial pathogens, pathogenesis, diagnostic approaches, antimicrobial resistance, emerging infections, infection prevention, and innovative technologies for future infectious disease management. The schematic illustrates [Figure 1] the progression of infectious disease from pathogen exposure and host–pathogen interaction through infection and clinical manifestations, followed by specimen collection, conventional and molecular diagnosis, pathogen identification, antimicrobial susceptibility testing, targeted therapy, infection prevention, epidemiological surveillance, and outbreak response. The framework highlights the interconnected roles of laboratory diagnosis, clinical management, infection control, and public health surveillance in comprehensive infectious disease management.

Major Groups of Medically Important Microorganisms

Bacteria: Bacteria constitute one of the largest and most clinically significant groups of medically important microorganisms. They are responsible for a wide range of infectious diseases affecting virtually every organ system, from relatively uncomplicated infections such as urinary tract infections, skin and soft-tissue infections, and gastroenteritis to severe and life-threatening conditions including pneumonia, meningitis, endocarditis, bloodstream infections, wound infections, and sepsis.[20] Important bacterial pathogens include Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Streptococcus pneumoniae, Salmonella spp., Shigella spp., Neisseria meningitidis, and Mycobacterium tuberculosis.[21] Gram-negative organisms such as K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli are particularly important in healthcare settings because they are increasingly associated with difficult-to-treat bloodstream, respiratory, urinary, wound, and surgical-site infections.[22] The clinical manifestations of bacterial infections depend on the species, virulence factors, site of infection, and host immune status. Bacteria can cause disease through direct invasion and destruction of host tissues, secretion of exotoxins, production of endotoxin, intracellular survival, biofilm formation, immune evasion, or induction of excessive inflammatory and immune responses.[23] Some organisms, such as S. aureus and S. pyogenes, produce potent toxins that contribute substantially to tissue damage and systemic disease, whereas organisms such as M. tuberculosis can establish persistent intracellular infections and cause chronic disease.[24] Biofilm formation is another important pathogenic mechanism, particularly in infections associated with implanted medical devices, chronic wounds, urinary catheters, and prosthetic materials, where bacteria can become less susceptible to antimicrobial treatment and host immune responses.[25]

A major challenge in contemporary bacterial infectious disease management is the rapid emergence and dissemination of antimicrobial resistance (AMR). Resistant bacteria can arise through spontaneous genetic mutations or acquisition of resistance determinants through horizontal gene transfer, including plasmid-mediated transmission. Mechanisms of resistance include enzymatic drug inactivation, alteration of antimicrobial targets, reduced membrane permeability, active efflux, and metabolic bypass pathways. The problem is no longer restricted to individual hospitals; resistant organisms can circulate between healthcare facilities, communities, animals, food systems, and the environment, making AMR an important One Health concern.[26,27] The current AMR scenario highlights the increasing difficulty of treating bacterial infections. WHO's updated 2024 bacterial priority pathogens list identifies 24 antibiotic-resistant bacterial pathogens across 15 families and categorizes them into critical, high, and medium-priority groups to guide research, diagnostics, antimicrobial development, and public-health interventions.[28] Recent WHO estimates indicate that bacterial AMR was associated with more than 4.7 million deaths globally in 2021,[29] while approximately one in six laboratory-confirmed

ISSN (O): 2687-5365; ISSN (P): 2753-6556

bacterial infections worldwide was resistant to antibiotics in 2023, demonstrating the substantial and continuing global burden of drug-resistant bacterial disease.[30]

Among healthcare-associated pathogens, multidrug-resistant A. baumannii, carbapenem-resistant Enterobacterales, and drug-resistant P. aeruginosa are of particular concern because therapeutic options may be limited. Similarly, methicillin-resistant S. aureus (MRSA) continues to cause serious community- and healthcare-associated infections, while extended-spectrum β-lactamase (ESBL)-producing E. coli and K. pneumoniae complicate the treatment of urinary, bloodstream, and intra-abdominal infections.[15] Drug-resistant M. tuberculosis remains another major challenge; the WHO 2025 Global Tuberculosis Report estimated approximately 390,000 people developed rifampicin-resistant or multidrug-resistant tuberculosis in 2024.[31]

The emergence of AMR has consequently increased the importance of rapid and accurate bacterial detection, identification, and antimicrobial susceptibility testing (AST). Conventional culture-based methods remain fundamental to clinical microbiology, but they may require considerable time, particularly when identification and susceptibility testing are performed sequentially.[32] Molecular methods, mass spectrometry, multiplex diagnostic platforms, biosensors, and fluorescence-based approaches are increasingly being investigated to shorten diagnostic turnaround times and enable earlier targeted therapy.[33] Rapid diagnostics are particularly important for bloodstream infections, sepsis, respiratory infections, and infections caused by multidrug-resistant organisms, where delays in appropriate treatment can adversely affect clinical outcomes.[11] In addition, bacterial surveillance has become an essential component of infection prevention and antimicrobial stewardship. Continuous monitoring of bacterial species distribution, resistance profiles, emerging resistance mechanisms, and transmission patterns supports hospital antibiograms, outbreak investigation, infection-control strategies, and evidence-based antimicrobial selection.[34] In India, AMR surveillance and antimicrobial stewardship are increasingly emphasized within the broader national response to AMR, including laboratory surveillance, infection prevention and control, optimization of antimicrobial use, and development of diagnostic and research capacity.[35] Thus, bacteria remain a major and evolving component of the global infectious disease burden. The combination of diverse pathogenic mechanisms, healthcare-associated transmission, biofilm formation, increasing multidrug resistance, and the movement of resistant organisms across human, animal, and environmental settings emphasizes the need for rapid, sensitive, specific, and affordable bacterial detection and characterization methods. These needs have stimulated considerable interest in advanced diagnostic technologies, including fluorescence-based detection, nanomaterial-enabled biosensing, and label-free approaches that can complement conventional microbiological methods.

Viruses: Viruses are a diverse group of infectious agents that are generally much smaller than bacteria and lack independent metabolic and reproductive systems. They are obligate intracellular pathogens that depend on host cells for replication and can infect virtually every major organ system in humans.[36] Clinically important viral pathogens include influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), dengue virus, hepatitis A, B, and C viruses, human immunodeficiency virus (HIV), herpes simplex viruses, human papillomavirus (HPV), and several emerging and re-emerging arboviruses such as chikungunya, Zika, and Japanese encephalitis viruses.[37] The clinical importance of viral infections has increased considerably because of their ability to spread rapidly through populations, undergo genetic variation, cross species barriers, and emerge in new geographical regions. Viral infections can produce a broad spectrum of clinical manifestations, ranging from asymptomatic infection and mild self-limiting illness to severe systemic disease, organ failure, and death. Respiratory viruses such as influenza viruses, RSV, and SARS-CoV-2 can cause upper and lower respiratory tract infections, with severe disease particularly affecting infants, older adults, and individuals with underlying conditions.[38,39]

Arboviral infections such as dengue, chikungunya, and Zika are important public-health concerns in tropical and subtropical regions because of their association with mosquito transmission and seasonal outbreaks.[40] Hepatitis viruses can produce acute and chronic liver disease, with persistent infection potentially progressing to cirrhosis and hepatocellular carcinoma. Similarly, HIV causes progressive immune dysfunction, while oncogenic HPV types are associated with cervical and several other anogenital and oropharyngeal cancers.[41] Viral pathogenesis depends on several factors, including the tropism of the virus, receptor availability on host cells, replication strategy, viral virulence factors, host immune responses, and the ability of the virus to evade immune recognition. Some viruses establish persistent or latent infections within host tissues and may reactivate later. Herpes viruses are prominent examples of viruses capable of establishing lifelong latency.[42] Other viruses, including influenza viruses and coronaviruses, can undergo genetic changes that influence transmissibility, antigenicity, and susceptibility to existing immunity. The emergence of novel viral variants or viruses capable of infecting new hosts presents an ongoing challenge for global health surveillance and preparedness.[43]

Accurate and timely laboratory diagnosis is essential for the management and control of viral infections. Conventional diagnostic approaches include virus isolation, antigen detection, antibody-based

ISSN (O): 2687-5365; ISSN (P): 2753-6556

serological assays, and microscopic or cytological examination in selected infections. However, many viruses cannot be readily cultured using routine laboratory methods, and culture-based diagnosis may require considerable time and specialized facilities. Molecular amplification techniques, particularly reverse-transcription polymerase chain reaction (RT-PCR) and real-time PCR, have therefore become important tools for detecting viral nucleic acids with high sensitivity and specificity.[44] These methods are particularly valuable during the early stages of infection, when viral nucleic acid may be detectable before a strong antibody response develops. Antigen detection assays provide a relatively rapid means of identifying viral infections and can be useful in point-of-care and outbreak settings. Serological methods, including enzyme-linked immunosorbent assays (ELISA), chemiluminescent assays, and rapid antibody tests, are particularly useful for determining previous exposure, assessing immune responses, and diagnosing infections in which viral nucleic acid may no longer be detectable. More recently, next-generation sequencing and whole-genome sequencing have expanded the ability to characterize viral genomes, identify genetic variants, investigate transmission pathways, and monitor the emergence of antiviral resistance.[45]

The recent global experience with COVID-19 demonstrated the importance of rapid molecular diagnostics, genomic surveillance, and scalable laboratory capacity during viral outbreaks. At the same time, the continuing circulation of influenza, RSV, dengue, and other endemic and emerging viruses emphasizes the need for diagnostic systems that are rapid, sensitive, specific, affordable, and suitable for decentralized testing. In resource-limited settings, diagnostic approaches that require minimal sample processing, simple instrumentation, and short turnaround times are particularly valuable.[46] Despite major advances in virology and diagnostic technology, viral infections remain a significant global health challenge. Emerging viruses, changing transmission patterns, climate-related expansion of vector-borne diseases, international travel, urbanization, and increasing interactions between humans and animal reservoirs can facilitate the emergence and spread of viral pathogens. Consequently, continued development of rapid molecular, antigen-based, serological, sequencing, biosensor, and fluorescence-based diagnostic technologies is important for early detection, outbreak response, clinical management, and effective public-health surveillance.[47]

Fungi: Fungi are eukaryotic microorganisms that represent an important group of medically significant pathogens. Although many fungal species are harmless environmental organisms or components of the normal human microbiota, several can cause superficial, mucosal, subcutaneous, and invasive infections.[48] The clinical importance of fungal diseases has increased substantially with the growing population of immunocompromised patients, including individuals receiving chemotherapy, organ or stem-cell transplantation, prolonged corticosteroid or immunosuppressive therapy, intensive medical care, or long-term antimicrobial treatment. Major medically important fungal pathogens include Candida spp., Aspergillus spp., Cryptococcus neoformans, dermatophytes such as Trichophyton and Microsporum, and emerging pathogenic moulds such as Mucorales and Fusarium spp.[49]

Fungal infections can range from relatively localized superficial diseases, such as dermatophytosis and oral or vaginal candidiasis, to severe invasive infections involving the bloodstream, lungs, brain, or multiple organs.[50] Candida spp. are important causes of mucosal infections as well as invasive candidiasis and candidemia, particularly among hospitalized and critically ill patients. Aspergillus spp. primarily cause pulmonary disease but can disseminate to other organs in severely immunocompromised individuals. C. neoformans is an important opportunistic pathogen capable of causing cryptococcal meningitis, particularly in individuals with impaired cellular immunity. In addition, mucormycosis caused by fungi belonging to the order Mucorales can result in rapidly progressive rhino-orbital, pulmonary, cutaneous, or disseminated disease, with particularly severe outcomes in susceptible individuals.[51] The pathogenesis of fungal infections is influenced by fungal virulence factors, host immune status, anatomical barriers, and the ability of fungi to adhere to tissues and medical devices. Several pathogenic fungi can form biofilms, which enhance persistence and reduce susceptibility to antifungal treatment. The increasing recognition of antifungal resistance, particularly among Candida species, represents an additional challenge for clinical management. Resistance may arise through alterations in antifungal targets, increased drug efflux, changes in membrane composition, biofilm-associated mechanisms, and genetic adaptation during prolonged therapy.[52] Consequently, accurate species-level identification and antifungal susceptibility testing are increasingly important for selecting appropriate treatment. Diagnosis of fungal infections can be challenging because their clinical manifestations are often nonspecific and may resemble bacterial or viral diseases. Conventional laboratory diagnosis relies on direct microscopic examination, fungal culture, and histopathological evaluation of clinical specimens. Culture remains important for organism identification and susceptibility testing but may require several days or longer depending on the organism. Histopathology can provide evidence of tissue invasion and is particularly valuable in invasive disease. However, these approaches may have limitations in sensitivity, turnaround time, or the requirement for specialized expertise. Advances in diagnostic microbiology have introduced several complementary approaches, including fungal antigen detection, molecular assays, and biomarker-based testing. Detection of fungal components such as galactomannan and β-D-glucan can support the

ISSN (O): 2687-5365; ISSN (P): 2753-6556

diagnosis of selected invasive fungal infections, while nucleic-acid amplification methods can provide more rapid and specific detection. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has also improved the rapid identification of many cultured fungal isolates. Antifungal susceptibility testing remains essential when resistant organisms are suspected or when treatment failure occurs.[53] The current fungal disease scenario highlights the need for early and reliable diagnosis, particularly because delayed recognition of invasive fungal infections can result in substantial morbidity and mortality. Increasing antifungal resistance, emergence of previously uncommon fungal pathogens, expansion of susceptible patient populations, and limitations of conventional diagnostic methods have created a need for rapid, sensitive, specific, and accessible diagnostic technologies. These challenges have stimulated research into molecular diagnostics, biosensors, nanotechnology-based platforms, and fluorescence-based detection systems that may facilitate earlier recognition and characterization of fungal pathogens.[54]

Parasites: Parasitic infections remain important causes of morbidity and mortality, particularly in tropical and subtropical regions where climatic conditions, inadequate sanitation, contaminated water, poor housing, and limited access to healthcare facilitate transmission. Medically important parasites are broadly classified into protozoa and helminths. Important protozoan pathogens include Plasmodium spp., the causative agents of malaria; Entamoeba histolytica, associated with amoebic dysentery and liver abscess; Giardia duodenalis, a major cause of intestinal giardiasis; Leishmania spp., responsible for visceral and cutaneous leishmaniasis; and Trypanosoma spp., which cause African trypanosomiasis and Chagas disease. Medically significant helminths include Ascaris lumbricoides, Schistosoma spp., Taenia spp., and filarial parasites such as Wuchereria bancrofti and Brugia spp.[55] These infections can produce a wide spectrum of clinical manifestations, ranging from asymptomatic or mild intestinal disease to severe anemia, malnutrition, hepatosplenic disease, neurological complications, and chronic organ damage. Malaria remains one of the most important parasitic diseases globally, with Plasmodium falciparum and P. vivax accounting for a substantial proportion of human infections. Increasing drug resistance in some malaria parasites further complicates disease control and highlights the importance of accurate diagnosis and appropriate treatment.[56]

Traditional laboratory diagnosis of parasitic infections relies heavily on microscopic examination of blood, stool, urine, or tissue specimens. Although microscopy remains widely used because of its relatively low cost and accessibility, its sensitivity can be affected by parasite burden, specimen quality, timing of collection, and examiner expertise.[57] Antigen detection and serological assays provide useful alternatives or complementary approaches, particularly when parasite numbers are low or microscopy is difficult. Molecular methods, including conventional PCR, real-time PCR, and multiplex nucleic-acid amplification assays, offer improved sensitivity and specificity and can facilitate species-level identification. Advances in molecular diagnostics, biosensors, and fluorescence-based detection systems are therefore increasingly being explored for rapid and reliable parasite detection. Early diagnosis is essential for appropriate treatment, prevention of transmission, epidemiological surveillance, and control of parasitic diseases, particularly in endemic regions. The [Table 1] summarizes the principal groups of microorganisms of medical importance, including bacteria, viruses, fungi, protozoa, helminths, and ectoparasites, along with representative pathogenic species and their major associated human diseases. These microorganisms encompass a broad range of infectious agents responsible for community-acquired, healthcare-associated, opportunistic, vector-borne, and emerging infections.[58] The examples provided are representative and are not intended to constitute an exhaustive list of medically important pathogens.

Table 1: Major groups of medically important microorganisms and representative diseases.

Microorganism group	Representative pathogens	Major diseases / clinical conditions
Bacteria	Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Salmonella spp.	Urinary tract infections, pneumonia, wound infections, bloodstream infections, sepsis, tuberculosis, gastroenteritis, meningitis
Viruses	Influenza virus, respiratory syncytial virus, SARS-CoV-2, dengue virus, hepatitis B and C viruses, HIV, herpesviruses	Influenza, respiratory infections, COVID-19, dengue, viral hepatitis, HIV/AIDS, herpesvirus infections
Fungi	Candida spp., Aspergillus spp., Cryptococcus neoformans, dermatophytes, Mucorales	Candidiasis, candidemia, invasive aspergillosis, cryptococcosis, dermatophytosis, mucormycosis
Protozoa	Plasmodium spp., Entamoeba histolytica, Giardia duodenalis, Leishmania spp., Trypanosoma spp.	Malaria, amoebiasis, giardiasis, leishmaniasis, African trypanosomiasis, Chagas disease
Helminths	Ascaris lumbricoides, Schistosoma spp., Taenia spp., Wuchereria bancrofti, Brugia spp.	Ascariasis, schistosomiasis, taeniasis, cysticercosis, lymphatic filariasis
Ectoparasites	Sarcoptes scabiei, Pediculus humanus, ticks, fleas	Scabies, pediculosis, tick-associated diseases, flea-associated infections

ISSN (O): 2687-5365; ISSN (P): 2753-6556

Microbial pathogenesis and host-pathogen interactions: Infectious disease results from a dynamic interaction between microbial virulence properties and host susceptibility. The outcome of infection depends on the ability of a microorganism to colonize the host, overcome physical and immune barriers, acquire nutrients, multiply, and evade or manipulate host defense mechanisms. Important microbial determinants of pathogenicity include adhesins, capsules, toxins, secretion systems, surface-associated structures, biofilm formation, immune evasion mechanisms, and strategies that enable intracellular survival. Conversely, host factors such as age, immune status, nutritional condition, underlying diseases, genetic susceptibility, and disruption of normal anatomical barriers can strongly influence the severity and progression of infection.[59]

Adherence to host tissues is commonly one of the earliest steps in microbial infection. Bacterial surface structures, including pili, fimbriae, flagella, adhesins, and other cell-surface proteins, facilitate attachment to specific receptors on host cells and extracellular matrix components. This initial interaction enables microorganisms to resist mechanical clearance and establish colonization. Following attachment, pathogens may invade epithelial or deeper tissues, enter host cells, or exploit specialized intracellular niches. Some microorganisms also produce extracellular enzymes and toxins that facilitate tissue penetration, cellular damage, nutrient acquisition, and dissemination within the host.[60] Biofilm formation represents another important mechanism of microbial persistence. Biofilms are structured microbial communities enclosed within an extracellular polymeric matrix composed of polysaccharides, proteins, nucleic acids, and other biomolecules. The biofilm environment can enhance microbial attachment and provide protection against antimicrobial agents, host immune mechanisms, environmental stress, and physical removal. Consequently, biofilms are strongly associated with chronic and recurrent infections, particularly those involving urinary catheters, vascular devices, prosthetic joints, dental surfaces, implants, and chronic wounds. Biofilm-associated microorganisms may therefore require prolonged or combination antimicrobial therapy and, in some cases, removal of infected devices.[61]

The host immune response is equally important in determining the outcome of infection. Innate immune mechanisms, including epithelial barriers, phagocytic cells, complement, inflammatory mediators, and pattern-recognition receptors, provide the initial response to invading microorganisms. Adaptive immunity subsequently generates pathogen-specific cellular and humoral responses that contribute to elimination and immunological memory. However, pathogens may evade these defenses through antigenic variation, intracellular survival, capsule formation, inhibition of phagocytosis, modification of surface structures, or manipulation of host signaling pathways. At the same time, excessive or dysregulated immune activation can cause substantial tissue injury and contribute to severe manifestations such as sepsis, inflammatory organ damage, and systemic disease.[62] Understanding microbial pathogenesis and host-pathogen interactions is therefore fundamental to infectious disease research and diagnostic development. Characterizing microbial surface structures and interactions with host tissues can provide important information about colonization, virulence, persistence, and disease progression. These interactions also provide potential targets for the development of novel antimicrobial agents, vaccines, biosensors, and rapid diagnostic technologies capable of detecting pathogens or their characteristic surface-associated structures at an early stage of infection.[63] The [Figure 2] depicts the major stages of infectious disease development, beginning with microbial adherence to host cells through surface-associated structures such as pili, fimbriae, flagella, and adhesins, followed by colonization, tissue invasion, intracellular survival, multiplication, and biofilm formation. Major microbial virulence factors, including capsules, toxins, secretion systems, immune evasion mechanisms, and intracellular survival strategies, contribute to pathogen persistence and disease progression. Host susceptibility factors and innate and adaptive immune responses influence the outcome of infection, which may range from asymptomatic colonization or clearance to acute, chronic, or severe systemic disease.[64]



Figure 2: Schematic illustration of microbial pathogenesis and host–pathogen interactions.

Clinical Microbiology and Laboratory Diagnosis: Accurate diagnosis is fundamental to effective infectious disease management. Conventional microbiological diagnosis includes specimen collection, microscopy, culture, biochemical identification, antigen detection, and antimicrobial susceptibility testing.

Microscopy and Staining: Microscopy remains a fundamental, rapid, and cost-effective method for the preliminary diagnosis of infectious diseases. Direct microscopic examination of clinical specimens can provide immediate information regarding the presence, morphology, arrangement, and approximate abundance of microorganisms. Gram staining is one of the most widely used techniques in bacterial diagnosis and differentiates bacteria into Gram-positive and Gram-negative groups based on differences in their cell-wall structure. Gram-positive bacteria generally appear purple, whereas Gram-

ISSN (O): 2687-5365; ISSN (P): 2753-6556

negative bacteria appear pink or red after counterstaining. Gram staining also provides useful information about bacterial morphology and arrangement, such as cocci in clusters or chains and bacilli, which can assist in preliminary identification and selection of empirical antimicrobial therapy.[65] Other specialized staining techniques are important for specific pathogens. Ziehl–Neelsen staining is widely used for detecting acid-fast bacilli, particularly Mycobacterium tuberculosis. Fungal infections can be investigated using potassium hydroxide (KOH), periodic acid–Schiff (PAS), and Gomori methenamine silver (GMS) stains to demonstrate fungal cells and hyphae. Parasitic infections may be evaluated using wet mounts, iodine preparations, Giemsa staining, and other organism-specific techniques. Although microscopy is rapid and inexpensive, its sensitivity depends on specimen quality, organism burden, staining procedures, and observer expertise. Therefore, microscopic findings are frequently complemented by culture, antigen detection, molecular assays, or other confirmatory methods. Nevertheless, microscopy remains an essential first-line diagnostic approach, particularly in resource-limited settings and situations requiring rapid preliminary information.[66]

Culture-Based Diagnosis: Culture-based diagnosis remains a cornerstone of clinical microbiology and an important reference method for many bacterial and fungal infections. The process involves inoculation of clinical specimens onto appropriate culture media, followed by incubation under suitable environmental conditions to promote microbial growth. Isolation of viable organisms allows subsequent identification based on colony morphology, microscopic characteristics, biochemical reactions, automated systems, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). An important advantage of culture is that recovery of viable microorganisms enables antimicrobial susceptibility testing (AST), which supports selection of appropriate targeted therapy and detection of antimicrobial-resistant strains. Culture isolates can also be preserved for epidemiological investigations, outbreak characterization, molecular typing, and surveillance of emerging resistance.[67]

Despite these advantages, culture-based methods have several limitations. Microbial growth may require several hours to several days, depending on the organism and specimen type, resulting in delayed diagnosis and treatment decisions. Sensitivity may also be reduced when the microbial load is low or when specimens are collected after antimicrobial therapy has been initiated. Some fastidious, slow-growing, or non-cultivable microorganisms are difficult or impossible to recover using routine culture techniques. In addition, inappropriate specimen collection, transport, storage, or prior antimicrobial exposure can adversely affect recovery. Therefore, although culture remains essential for definitive diagnosis and susceptibility testing, it is increasingly complemented by rapid antigen-based, molecular, and other advanced diagnostic technologies to reduce turnaround time and improve detection.[68]

Immunological Methods: Immunological methods are important diagnostic approaches that detect either microbial antigens or host-generated antibodies in clinical specimens. These methods are widely used for the diagnosis of bacterial, viral, fungal, and parasitic infections because they can provide relatively rapid results and, in many settings, require less specialized equipment than conventional culture or molecular techniques. Common platforms include enzyme-linked immunosorbent assays (ELISA), enzyme immunoassays, chemiluminescent immunoassays, lateral-flow immune chromatographic tests, and other rapid diagnostic formats Antigen detection assays identify specific components of a microorganism, such as proteins or structural molecules, and can provide evidence of active or recent infection.[69] They are particularly useful when rapid diagnosis is required or when the pathogen is difficult to culture. Rapid immunochromatographic tests are widely used in point-of-care settings because they are generally simple to perform and can produce results within minutes. However, their sensitivity may be lower than that of molecular assays, particularly when the pathogen concentration is low.

Serological methods detect antibodies produced by the host in response to infection. Detection of pathogen-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) can assist in diagnosing infections, determining previous exposure, or assessing immune responses. Serology is particularly valuable when direct pathogen detection becomes difficult after the acute phase of infection or when the organism is present at low levels. Nevertheless, interpretation requires consideration of the timing of specimen collection, antibody kinetics, cross-reactivity, and previous exposure or vaccination. Thus, immunological methods often complement microscopy, culture, and molecular diagnostics to improve overall diagnostic accuracy.[70]

Molecular Diagnostics: Molecular diagnostics have transformed the detection and identification of infectious pathogens by enabling direct identification of microbial nucleic acids in clinical specimens. Polymerase chain reaction (PCR), reverse-transcription PCR (RT-PCR), quantitative PCR (qPCR), and multiplex PCR are among the most widely used nucleic-acid amplification technologies. These methods offer high analytical sensitivity and specificity and can detect microorganisms that are difficult, slow, or impossible to cultivate using conventional culture methods. Molecular testing can also provide results within a relatively short turnaround time, facilitating earlier clinical decision-making and targeted antimicrobial or antiviral therapy.[71] RT-PCR is particularly important for the detection of RNA viruses, including respiratory viruses and several arboviruses, whereas qPCR

ISSN (O): 2687-5365; ISSN (P): 2753-6556

provides both qualitative detection and quantitative or semi-quantitative measurement through real-time monitoring of amplification. Multiplex PCR further expands diagnostic capability by allowing simultaneous detection of multiple pathogens or resistance-associated targets in a single clinical specimen. This is particularly useful when patients present with nonspecific clinical symptoms and several pathogens may produce similar disease manifestations.[72]

Multiplex molecular platforms are increasingly applied to respiratory infections, bloodstream infections, gastrointestinal infections, sexually transmitted infections, and central nervous system infections.[72] Some advanced assays can simultaneously identify pathogens and selected antimicrobial-resistance determinants, providing clinically useful information earlier than conventional culture-based workflows. Despite these advantages, molecular diagnostics can be relatively expensive and may require specialized instruments, trained personnel, and appropriate quality-control systems. Detection of nucleic acid also does not always distinguish viable organisms from nonviable microbial material. Therefore, molecular methods are often used alongside culture, microscopy, antigen detection, and clinical assessment to provide comprehensive diagnosis and guide appropriate patient management.[73]

Next-Generation Sequencing and Metagenomics: Next-generation sequencing (NGS) has significantly expanded the capabilities of infectious disease diagnostics by enabling rapid and comprehensive analysis of microbial genomes. Unlike conventional diagnostic methods that generally target a specific pathogen, sequencing-based approaches can provide detailed genetic information that supports pathogen identification, characterization, and epidemiological investigation.[74] Whole-genome sequencing (WGS) can identify genetic variations within microbial populations and provide valuable information regarding pathogen evolution, transmission pathways, virulence-associated characteristics, and antimicrobial-resistance determinants. It is increasingly used for outbreak investigation, genomic surveillance, and tracking the emergence and spread of drug-resistant pathogens.[74,75]

Metagenomic sequencing represents a further advancement by enabling the detection and characterization of microbial nucleic acids directly from clinical specimens without requiring prior knowledge of the causative organism or conventional culture.[74] This approach can simultaneously identify bacteria, viruses, fungi, and parasites present in a specimen and may be particularly useful for patients with severe, unusual, or unexplained infections in which routine diagnostic testing has failed to establish an etiological diagnosis. Metagenomics can also provide information about mixed infections and the broader microbial composition of clinical samples.

Despite its considerable potential, widespread implementation of NGS and metagenomics faces several challenges. These include relatively high costs, complex sample preparation, the need for specialized sequencing infrastructure, large data volumes, bioinformatic expertise, contamination control, and difficulties in distinguishing clinically relevant organisms from background microbial DNA. Turnaround time and lack of standardized analytical and reporting workflows may also limit routine clinical application. Nevertheless, continuing advances in sequencing technologies, bioinformatics, automation, and data interpretation are expected to improve the accessibility and clinical utility of NGS-based infectious disease diagnostics.[74]

The diagnostic workflow [Figure 3] encompasses (4.1) microscopy and staining for rapid preliminary visualization and classification of microorganisms; (4.2) culture-based methods for pathogen isolation, identification, and antimicrobial susceptibility testing; (4.3) immunological methods for antigen or antibody detection; (4.4) molecular diagnostics for sensitive and specific detection of microbial nucleic acids; and (4.5) next-generation sequencing and metagenomic approaches for comprehensive pathogen identification, genomic characterization, epidemiological surveillance, and antimicrobial resistance analysis. These complementary approaches support accurate diagnosis, clinical decision-making, infection control, and public health surveillance.




Figure 3: Schematic illustration of laboratory diagnosis of infectious diseases.

Antimicrobial Resistance: Antimicrobial resistance (AMR) has emerged as one of the most significant challenges to the effective prevention and treatment of infectious diseases worldwide. It occurs when microorganisms develop the ability to survive or multiply despite exposure to antimicrobial agents that would normally inhibit or eliminate them. Although resistance is a natural evolutionary phenomenon, its development and dissemination have been accelerated by inappropriate and excessive antimicrobial use, inadequate infection prevention and control, poor adherence to treatment regimens, and transmission of resistant organisms within healthcare and community settings. AMR affects bacteria, viruses, fungi, and parasites; however, bacterial antimicrobial resistance represents a particularly important clinical and public-health concern because of the increasing prevalence of

ISSN (O): 2687-5365; ISSN (P): 2753-6556

multidrug-resistant organisms.[76] Resistance can develop through spontaneous genetic mutations or through acquisition of resistance determinants from other microorganisms. Horizontal gene transfer, including conjugation, transformation, and transduction, enables bacteria to exchange genetic material and rapidly acquire new resistance characteristics. Mobile genetic elements such as plasmids, transposons, integrons, and insertion sequences play important roles in the dissemination of resistance genes between bacterial strains and, in some circumstances, between different bacterial species. Selective pressure exerted by antimicrobial exposure promotes the survival and multiplication of resistant organisms while susceptible populations are eliminated, facilitating the expansion of resistant strains.[77]

Microorganisms employ several mechanisms to resist antimicrobial activity. These include enzymatic inactivation or modification of drugs, alteration of antimicrobial targets, reduced membrane permeability, active efflux of antimicrobial compounds, and metabolic bypass pathways. β-lactamase production is an important example of enzymatic resistance, in which bacterial enzymes hydrolyze β-lactam antibiotics. Extended-spectrum β-lactamases (ESBLs) can confer resistance to many penicillins and cephalosporins, while carbapenemases can compromise carbapenem-based therapy.[78] Alterations in antimicrobial targets, such as changes in penicillin-binding proteins, ribosomal structures, or DNA gyrase, can reduce drug binding and activity. Efflux pumps can actively remove antimicrobial compounds from bacterial cells, whereas reduced membrane permeability can limit drug entry. Biofilm formation can further increase antimicrobial tolerance by restricting drug penetration and promoting physiological states that reduce susceptibility.

Several multidrug-resistant organisms are of major clinical importance. These include methicillin-resistant Staphylococcus aureus (MRSA), ESBL-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), multidrug-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii. Such organisms are frequently associated with healthcare-acquired infections, including bloodstream infections, pneumonia, urinary tract infections, surgical-site infections, and wound infections. Treatment options for these infections may be limited, and infections caused by resistant organisms are often associated with prolonged hospitalization, increased healthcare costs, treatment failure, and higher mortality. The increasing burden of AMR highlights the importance of reliable antimicrobial susceptibility testing (AST).[79] Laboratory methods such as disk diffusion, broth microdilution, and automated susceptibility systems provide information regarding the susceptibility or resistance of an isolate to specific antimicrobial agents. Molecular and genomic approaches can additionally identify specific resistance genes or mutations and may assist in surveillance and outbreak investigations. Accurate AST results enable clinicians to select appropriate targeted therapy and reduce unnecessary exposure to broad-spectrum antimicrobials. Laboratory-generated antibiograms are also essential components of antimicrobial stewardship and infection-control programs. By summarizing local antimicrobial susceptibility patterns, antibiograms provide information that can guide empirical treatment before individual susceptibility results become available. Continuous surveillance of resistance trends enables healthcare institutions to recognize emerging resistance, revise empirical treatment guidelines, identify outbreaks, and evaluate the effectiveness of antimicrobial stewardship interventions. Addressing AMR requires an integrated “One Health” approach involving human health, veterinary medicine, agriculture, food production, and environmental surveillance.[80] Rational antimicrobial prescribing, improved infection prevention and control, vaccination, effective microbiological diagnosis, surveillance, antimicrobial stewardship, and development of new therapeutic and diagnostic technologies are all essential components of the response. In this context, rapid and accurate pathogen detection and resistance characterization are increasingly important for reducing inappropriate antimicrobial use and enabling timely, evidence-based treatment decisions. The schematic illustrates [Figure 4] the development and spread of antimicrobial resistance through selective pressure, survival and multiplication of resistant microorganisms, and horizontal transfer of resistance determinants. Major contributing factors include inappropriate antimicrobial use, healthcare-associated transmission, community spread, antimicrobial use in animals and agriculture, and environmental contamination. The figure also highlights the major consequences of antimicrobial resistance, including treatment failure, increased morbidity and mortality, prolonged hospitalization, and rising healthcare costs, together with key prevention and control measures such as antimicrobial stewardship, antimicrobial-resistance surveillance, infection prevention and control, vaccination, public-health education, and the One Health approach.[79]

ISSN (O): 2687-5365; ISSN (P): 2753-6556




Figure 4: Antimicrobial resistance: mechanisms, drivers, dissemination, and control strategies.

Antimicrobial Stewardship: Antimicrobial stewardship (AMS) refers to coordinated, evidence-based interventions designed to optimize the use of antimicrobial agents while ensuring effective treatment of infections and minimizing adverse consequences. The major principles of stewardship include selecting the appropriate antimicrobial agent, dose, route of administration, and duration according to the suspected or confirmed pathogen, infection site, patient characteristics, and antimicrobial susceptibility profile. Appropriate stewardship aims to maximize clinical outcomes while reducing unnecessary antimicrobial exposure, toxicity, healthcare costs, and the development and transmission of antimicrobial resistance.[81] Clinical microbiology laboratories play a central role in antimicrobial stewardship by providing timely and reliable information on pathogen identification and antimicrobial susceptibility. Conventional culture and antimicrobial susceptibility testing enable clinicians to modify empirical broad-spectrum therapy to more targeted treatment once the causative organism and susceptibility profile are established. Rapid diagnostic technologies, including molecular assays, multiplex platforms, and other advanced detection methods, can further shorten diagnostic turnaround times and facilitate earlier optimization of antimicrobial therapy.[82] Effective antimicrobial stewardship requires multidisciplinary collaboration among clinical microbiologists, physicians, pharmacists, infection-prevention and control professionals, epidemiologists, nurses, and hospital administrators. Institutional antibiograms can support empirical prescribing by providing information on local resistance patterns. Regular monitoring of antimicrobial consumption, resistance trends, treatment outcomes, and prescribing practices can help evaluate stewardship interventions. Thus, integrating rapid diagnostics, laboratory surveillance, infection-control measures, and evidence-based prescribing is essential for preserving antimicrobial effectiveness and improving patient outcomes.[83]

Emerging and Re-Emerging Infectious Diseases

Emerging infectious diseases are infections that have newly appeared in a population or have shown a substantial increase in incidence, geographical distribution, or public-health significance. Re-emerging infections are diseases that were previously controlled or had declined substantially but subsequently increased because of changes in epidemiological, environmental, or social conditions. These infections represent continuing challenges to global health because they can spread rapidly, overwhelm healthcare systems, and require rapid development of diagnostic, therapeutic, and preventive strategies.[84]

Several interconnected factors contribute to the emergence and re-emergence of infectious diseases. Climate variability and environmental change can alter the geographical distribution and seasonal activity of vectors and pathogens. Deforestation, urban expansion, agricultural practices, and increased human encroachment into wildlife habitats can enhance contact between humans, domestic animals, and wildlife reservoirs, facilitating zoonotic transmission.[85] Rapid population growth, population movement, international travel, migration, and global trade can further accelerate the spread of infectious agents across geographical boundaries. Changes in healthcare practices, immunosuppression, inadequate infection control, and antimicrobial resistance can also create conditions that favor the emergence of difficult to treat pathogens. Recent examples include novel coronavirus infections, emerging influenza strains, mpox, antimicrobial-resistant bacterial pathogens, invasive fungal infections, and expanding vector-borne diseases such as dengue and chikungunya.[86]

The increasing recognition of zoonotic disease emergence emphasizes the importance of the One Health approach, which integrates human, animal, and environmental health. Effective preparedness requires coordinated surveillance, rapid diagnostic capacity, genomic monitoring, vaccination, infection prevention, antimicrobial stewardship, and collaboration across multiple sectors. Strengthening these systems is essential for early detection, rapid response, and effective control of future infectious disease threats.[81]

Emerging technologies used in modern clinical microbiology for rapid and accurate pathogen detection. The [Table 2] summarizes the underlying principles, major diagnostic applications, advantages, and current limitations of advanced approaches, including rapid molecular diagnostics, multiplex PCR, isothermal amplification, next-generation sequencing, metagenomics, CRISPR-

ISSN (O): 2687-5365; ISSN (P): 2753-6556

based assays, biosensors, nanotechnology-based platforms, microfluidics, lateral-flow assays, artificial intelligence, digital microbiology, and portable point-of-care systems. These technologies have the potential to improve diagnostic sensitivity and specificity, reduce turnaround time, enable simultaneous detection of multiple pathogens, support antimicrobial-resistance surveillance, and facilitate decentralized testing, particularly in resource-limited healthcare settings. However, challenges related to cost, infrastructure, assay standardization, clinical validation, data interpretation, regulatory requirements, and integration into routine laboratory workflows remain important considerations.[87]

Table 2: Emerging technologies in clinical microbiology and pathogen detection

Microfluidic platforms	Miniaturized manipulation and analysis of small sample volumes	Integrated sample preparation and pathogen detection	Low reagent consumption, portability, and rapid testing	Fabrication complexity and integration
Lateral-flow assays	Immunochromatographic detection of antigens or antibodies	Point-of-care infectious disease testing	Low cost, simple operation, and rapid results	Lower sensitivity for low pathogen loads
Artificial intelligence and machine learning	Computational analysis of images, laboratory, clinical, and genomic data	Automated microscopy, pathogen identification, AMR prediction, surveillance	Automation, pattern recognition, and rapid data analysis	Data quality, bias, validation, cybersecurity
Digital microbiology	Integration of automated instruments, imaging, LIS, and surveillance systems	Laboratory workflow, surveillance, and outbreak detection	Improved efficiency, connectivity, and data management	Interoperability, infrastructure, and data security
Portable point-of-care platforms	Miniaturized molecular, immunological, or biosensor-based testing	Decentralized and resource-limited settings	Rapid, accessible, and minimal sample processing	Power supply, reagent stability, quality assurance

Vector-Borne and Tropical Infectious Diseases

Vector-borne diseases remain major public-health concerns, particularly in tropical and subtropical regions where climatic conditions, environmental factors, and socioeconomic conditions support the survival and transmission of arthropod vectors. Mosquitoes, ticks, sandflies, fleas, mites, and other arthropods can transmit a wide range of bacterial, viral, and parasitic pathogens. Changes in temperature, rainfall, land use, urbanization, population movement, and vector distribution can influence transmission patterns and contribute to the expansion of vector-borne diseases into new geographical areas.[88] Important vector-associated infections include dengue, malaria, chikungunya, Japanese encephalitis, leishmaniasis, scrub typhus, lymphatic filariasis, and various viral encephalitides. These infections can produce a broad spectrum of clinical manifestations, ranging from mild febrile illness to severe hemorrhage, neurological disease, organ dysfunction, and death. Co-circulation of multiple vector-borne pathogens can further complicate diagnosis because several infections may present with similar symptoms such as fever, headache, myalgia, rash, thrombocytopenia, or neurological manifestations.[89]

Laboratory diagnosis therefore plays an essential role in differentiating these infections. Depending on the pathogen and stage of illness, diagnostic approaches may include microscopy, antigen detection, molecular amplification techniques, serological assays, and pathogen-specific rapid diagnostic tests. Molecular methods are particularly valuable during the early phase of infection, whereas antibody-based testing can provide evidence of recent or previous exposure Accurate diagnosis is important for appropriate treatment, patient management, outbreak detection, and surveillance. Effective control of vector-borne diseases requires an integrated approach involving vector surveillance, environmental management, personal protection, vector-control measures, vaccination where available, health education, and timely laboratory diagnosis. Strengthening surveillance and diagnostic capacity is particularly important for detecting changes in disease distribution and responding rapidly to outbreaks in endemic and emerging regions.[90]

Healthcare-Associated Infections: Healthcare-associated infections (HAIs) are infections acquired during the provision of healthcare and represent a major challenge for hospitals and other healthcare facilities. They can occur in patients receiving inpatient or outpatient care and are frequently associated with invasive procedures, prolonged hospitalization, immunosuppression, and exposure to healthcare environments. Common HAIs include catheter-associated urinary tract infections (CAUTIs), central-line-associated bloodstream infections (CLABSIs), ventilator-associated pneumonia (VAP), surgical-site infections (SSIs), and infections caused by multidrug-resistant organisms. HAIs can result in prolonged hospital stays, increased healthcare costs, treatment failure, and substantial morbidity and mortality.[91] Effective prevention and control require a comprehensive infection-prevention strategy. Hand hygiene remains one of the most important measures for interrupting transmission of infectious agents between patients,

ISSN (O): 2687-5365; ISSN (P): 2753-6556

healthcare workers, and the environment. Appropriate use of personal protective equipment, safe injection practices, proper handling of healthcare waste, environmental cleaning, sterilization and disinfection of medical equipment, and adherence to isolation precautions are also essential. Appropriate insertion and maintenance of invasive devices and minimizing unnecessary device use can further reduce infection risk. Antimicrobial stewardship helps limit the selection and spread of resistant organisms within healthcare settings.[92] Clinical microbiology laboratories play a central role in HAI prevention by providing accurate and timely pathogen identification and antimicrobial susceptibility testing. Laboratory surveillance can detect unusual increases in specific pathogens or resistance patterns and support early recognition of outbreaks. Microbiological data also contribute to hospital antibiograms and infection-control decision-making. Close collaboration among microbiologists, clinicians, infection-control teams, nurses, pharmacists, and hospital administrators is therefore essential for reducing HAIs and improving patient safety.[93]

Infection Prevention and Control: Infection prevention and control (IPC) encompasses a coordinated set of evidence-based measures designed to prevent the acquisition, transmission, and spread of infectious diseases within healthcare facilities and the community. Effective IPC is particularly important in hospitals, where close patient contact, invasive procedures, immunocompromised populations, and antimicrobial exposure can facilitate transmission of pathogens, including multidrug-resistant organisms. Standard precautions form the foundation of IPC and should be applied to all patients regardless of their confirmed or suspected infection status. These include appropriate hand hygiene, use of personal protective equipment according to anticipated exposure, respiratory hygiene, safe injection practices, proper handling of sharps and healthcare waste, and appropriate cleaning and disinfection of patient-care environments and equipment.[94]

Appropriate patient isolation, cohorting, ventilation, and use of suitable personal protective equipment can reduce healthcare-associated transmission. Regular monitoring, staff training, compliance audits, and outbreak investigation are essential for evaluating and strengthening IPC programs. Vaccination remains one of the most effective strategies for preventing numerous infectious diseases by reducing susceptibility, severe disease, and transmission within populations.[95] Successful IPC requires continuous collaboration among microbiology laboratories, clinicians, nurses, infection-control professionals, public-health authorities, patients, and the wider community. Integration of laboratory surveillance, antimicrobial stewardship, vaccination programs, environmental monitoring, and health education provides a comprehensive approach to reducing infection transmission and improving public-health preparedness.

Advances in rapid and point-of-care diagnostics

The increasing need for early and accurate identification of infectious diseases has accelerated the development of rapid and point-of-care (POC) diagnostic technologies. Conventional laboratory methods may require centralized infrastructure, specialized personnel, and extended turnaround times, which can delay appropriate treatment and infection-control decisions. POC diagnostics aim to overcome these limitations by enabling testing closer to the patient and, in some cases, providing results within minutes to hours.[96] Major emerging approaches include lateral-flow assays, isothermal nucleic-acid amplification, biosensors, microfluidic platforms, CRISPR-based detection systems, and nanoparticle-enabled diagnostic assays. Lateral-flow devices are particularly attractive because they are inexpensive, portable, simple to operate, and require minimal instrumentation. Isothermal amplification techniques can amplify pathogen nucleic acids at a constant temperature, reducing the need for complex thermal cyclers. Biosensors combine biological recognition elements with signal-transduction systems to enable rapid detection of microbial targets, while microfluidic devices integrate sample processing, amplification, and detection within miniaturized platforms. CRISPR-based technologies are being explored for highly specific nucleic-acid detection, whereas nanoparticles can enhance signal generation and improve assay sensitivity.[97]

These technologies are particularly valuable in resource-limited and decentralized healthcare settings, where access to sophisticated laboratory infrastructure may be restricted. However, challenges involving analytical sensitivity, specificity, reagent stability, contamination control, validation, manufacturing, cost, and regulatory approval remain. Ideally, next-generation diagnostic systems should provide high sensitivity and specificity, minimal sample preparation, short turnaround time, portability, affordability, and simple operation. Integration of these characteristics could facilitate earlier diagnosis, targeted treatment, outbreak detection, and improved infectious-disease surveillance.[98]

Artificial intelligence and digital microbiology

Artificial intelligence (AI), machine learning (ML), and digital technologies are increasingly being explored to improve infectious disease diagnosis, surveillance, and laboratory workflows. AI-based systems can analyze large and complex datasets more rapidly than conventional approaches and may support the identification of clinically relevant patterns that are difficult to recognize manually. In microbiology, important applications include automated interpretation of microscopy and culture images, microbial identification, prediction of antimicrobial resistance, analysis of genomic and metagenomic data, outbreak detection, and clinical

ISSN (O): 2687-5365; ISSN (P): 2753-6556

decision support. Image-based algorithms can assist in recognizing bacterial morphology, fungal structures, parasites, and other microscopic features, potentially improving diagnostic consistency and reducing workload.[99] Digital microbiology also enables integration of automated identification platforms, antimicrobial susceptibility testing systems, laboratory information management systems, electronic health records, imaging technologies, and genomic surveillance databases. Such integration can facilitate real-time monitoring of pathogen distribution and antimicrobial resistance patterns, support outbreak investigation, and improve communication of laboratory results to clinicians. Machine-learning models may additionally assist in predicting resistance profiles and identifying patients at increased risk of infection with multidrug-resistant organisms, thereby supporting antimicrobial stewardship and infection-control interventions.[100]

Despite these opportunities, several challenges must be addressed before widespread clinical implementation. Data quality, standardized datasets, algorithmic bias, model interpretability, external validation, interoperability, cybersecurity, patient privacy, and regulatory requirements are important considerations. AI systems should be evaluated using diverse clinical datasets to ensure reliable performance across different populations and healthcare settings. Ultimately, AI should complement rather than replace microbiological expertise, with appropriate human oversight and clinical validation. Responsible integration of AI and digital microbiology has the potential to improve diagnostic accuracy, laboratory efficiency, surveillance capacity, and timely clinical decision-making.[101]

Future Perspectives: The future of medical microbiology is expected to be increasingly shaped by rapid molecular diagnostics, genomic surveillance, artificial intelligence, biosensors, nanotechnology, and precision antimicrobial therapy. Integration of phenotypic laboratory findings with genomic and epidemiological data may enable more accurate prediction of antimicrobial resistance, pathogen transmission, and treatment response. Rapid sequencing and metagenomic approaches could further improve the identification of unusual, mixed, or previously unrecognized infections. The development of label-free, highly sensitive, and multiplex pathogen detection technologies may reduce diagnostic turnaround time while minimizing complex sample preparation. Portable and point-of-care platforms could facilitate decentralized testing, particularly in rural and resource-limited settings where access to centralized laboratories is limited. Integration of microfluidics, biosensors, fluorescence-based detection, and nanomaterials may contribute to the development of compact and user-friendly diagnostic systems.

At the population level, combining clinical microbiology data with epidemiological, genomic, and digital surveillance systems could enable earlier detection of outbreaks, emerging pathogens, and antimicrobial-resistance trends. These advances, supported by standardized laboratory practices and interdisciplinary collaboration, have the potential to transform infectious disease diagnosis, surveillance, treatment, and prevention while improving preparedness for future infectious threats.

Challenges and Research Priorities: Despite substantial advances in diagnostic technologies and infectious disease management, several challenges continue to limit effective microbiological diagnosis and control. These include unequal access to laboratory infrastructure, limited diagnostic capacity in resource-constrained settings, increasing antimicrobial resistance, prolonged diagnostic turnaround times, inadequate surveillance systems, and the emergence of novel and re-emerging pathogens. Addressing these challenges requires coordinated efforts across clinical, laboratory, technological, and public-health sectors. Future research should prioritize the development of rapid, sensitive, specific, affordable, and portable diagnostic platforms, particularly for decentralized and point-of-care applications. Improved detection and characterization of antimicrobial-resistant pathogens, combined with genomic surveillance and molecular epidemiology, are essential for monitoring resistance and transmission. Research into novel antimicrobials, antimicrobial alternatives, vaccines, and innovative infection-prevention technologies should also be strengthened. Integration of artificial intelligence, biosensors, microfluidics, and advanced molecular diagnostics may further improve diagnostic efficiency. At the population level, integrated One Health surveillance should connect human, animal, and environmental health data. Strengthening laboratory quality-management systems, standardization, biosafety, workforce training, and capacity building will remain essential for ensuring reliable diagnostics and sustainable infectious disease preparedness.

CONCLUSION

Medical microbiology remains fundamental to the diagnosis, treatment, prevention, and surveillance of infectious diseases. The continuing emergence of antimicrobial resistance, novel pathogens, healthcare-associated infections, and climate-sensitive infectious diseases demonstrates the need for sustained investment in microbiological research and laboratory capacity. Conventional culture and microscopy remain important, but they are increasingly complemented by molecular diagnostics, genomic sequencing, biosensors, metagenomics, and artificial intelligence. A coordinated approach integrating microbiology, clinical medicine, epidemiology, public health, genomics, environmental surveillance, and One Health principles will be essential for addressing

ISSN (O): 2687-5365; ISSN (P): 2753-6556

future infectious disease threats. Continued innovation in rapid pathogen detection, antimicrobial susceptibility testing, surveillance, and infection prevention has the potential to substantially improve patient outcomes and global preparedness for emerging infectious diseases.

REFERENCES

1. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, Wesolowski A. Infectious disease in an era of global change. Nature reviews microbiology. 2022 Apr;20(4):193-205.
2. Bloom DE, Cadarette D. Infectious disease threats in the twenty-first century: strengthening the global response. Frontiers in immunology. 2019 Mar 28;10:549.
3. Alara JA, Alara OR. An overview of the global alarming increase of multiple drug resistant: a major challenge in clinical diagnosis. Infectious Disorders-Drug TargetsDisorders). 2024 May 1;24(3):26-42.
4. Bianconi I, Aschbacher R, Pagani E. Current uses and future perspectives of genomic technologies in clinical microbiology. Antibiotics. 2023 Oct 30;12(11):1580.
5. Soni J, Sinha S, Pandey R. Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes. Frontiers in Microbiology. 2024 Feb 20;15:1370818.
6. Baral B, Mamale K, Gairola S, Chauhan C, Dey A, Kaundal RK. Infectious diseases and its global epidemiology. InNanostructured drug delivery systems in infectious disease treatment 2024 Jan 1 (pp. 1-24). Academic Press.
7. Yadav S, Qidwai T. Parasitic and Fungal Infections of the CNS: Insights Into Pathogens, Diagnosis, Treatment, and Future Prospects. Common Infectious Diseases of the Central Nervous System: Pathologies, Diagnostics, and Therapeutics. 2026:159-92.
8. Dunachie SJ, Esmail H, Corrigan R, Dudareva M. Infectious disease. InMedicine for Finals and Beyond 2022 Jun 19 (pp. 21-82). CRC Press.
9. Firacative C. Invasive fungal disease in humans: are we aware of the real impact?. Memórias do Instituto Oswaldo Cruz. 2020 Oct 9;115:e200430.
10. Schulze A, Mitterer F, Pombo JP, Schild S. Biofilms by bacterial human pathogens: Clinical relevance-development, composition and regulation-therapeutical strategies. Microbial Cell. 2021 Feb 1;8(2):28.
11. Gajic I, Jovicevic M, Kekic D, Kabic J, Vicic I, Lukovic B, Tomic A, Sovljanski O, Skoric M, Sikanic I, Jankovic M. Evolving Approaches to Bacterial Identification: A Review of Classical and Modern Techniques. International Journal of Molecular Sciences. 2026 Jun 4;27(11):5092.
12. Rajapaksha P, Elbourne A, Gangadoo S, Brown R, Cozzolino D, Chapman J. A review of methods for the detection of pathogenic microorganisms. Analyst. 2019 Jan 14;144(2):396-411.
13. Hilt EE, Ferrieri P. Next generation and other sequencing technologies in diagnostic microbiology and infectious diseases. Genes. 2022 Aug 31;13(9):1566.
14. Belay WY, Getachew M, Tegegne BA, Teffera ZH, Dagne A, Zeleke TK, Abebe RB, Gedif AA, Fenta A, Yirdaw G, Tilahun A. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review. Frontiers in pharmacology. 2024 Aug 16;15:1444781.
15. Birlutiu V, Birlutiu RM. An overview of the epidemiology of multidrug resistance and bacterial resistance mechanisms: what solutions are available? A comprehensive review. Microorganisms. 2025 Sep 19;13(9):2194.
16. De Souza WM, Weaver SC. Effects of climate change and human activities on vector-borne diseases. Nature reviews microbiology. 2024 Aug;22(8):476-91.
17. Williams PC, Bartlett AW, Howard-Jones A, McMullan B, Khatami A, Britton PN, Marais BJ. Impact of climate change and biodiversity collapse on the global emergence and spread of infectious diseases. Journal of paediatrics and child health. 2021 Nov;57(11):1811-8.
18. Hassan YM, Mohamed AS, Hassan YM, El-Sayed WM. Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. Clinical and experimental medicine. 2025 Jan 9;25(1):33.
19. Kardjadj M. Advances in point-of-care infectious disease diagnostics: integration of technologies, validation, artificial intelligence, and regulatory oversight. Diagnostics. 2025 Nov 10;15(22):2845.
20. Pieniążek JM, Padkowska A, Dobosz M, Arciszewska K, Buczkowski J, Miazga M, Paprocki M, Mataczyńska A. Overview Of The Main Bacterial Infections In Humans. Quality in Sport. 2024 Sep 26;23:54786-.
21. Ikuta KS, Swetschinski LR, Aguilar GR, Sharara F, Mestrovic T, Gray AP, Weaver ND, Wool EE, Han C, Hayoon AG, Aali A. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2022 Dec 17;400(10369):2221-48.
22. Bassetti M, Vena A, Sepulcri C, Giacobbe DR, Peghin M. Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance. Antibiotics. 2020 Sep 22;9(9):632.
23. Ghazaei C. Advances in the study of bacterial toxins, their roles and mechanisms in pathogenesis. The Malaysian journal of medical sciences: MJMS. 2022 Feb 23;29(1):4.
24. Rahman MA, Sarker A, Ayaz M, Shatabdy AR, Haque N, Jalouli M, Rahman MH, Mou TJ, Dey SK, Hoque Apu E, Zafar MS. An update on the study of the molecular mechanisms involved in autophagy during bacterial pathogenesis. Biomedicines. 2024 Aug 5;12(8):1757.
25. Mishra A, Aggarwal A, Khan F. Medical device-associated infections caused by biofilm-forming microbial pathogens and controlling strategies. Antibiotics. 2024 Jul 4;13(7):623.
26. Galgano M, Pellegrini F, Catalano E, Capozzi L, Del Sambro L, Sposato A, Lucente MS, Vasinioti VI, Catella C, Odigie AE, Tempesta M. Acquired bacterial resistance to antibiotics and resistance genes: from past to future. Antibiotics. 2025 Feb 21;14(3):222.
27. Zhu Y, Huang WE, Yang Q. Clinical perspective of antimicrobial resistance in bacteria. Infection and drug resistance. 2022 Jan 1:735-46.
28. Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, Boccia S, Castillo-Polo JA, Magrini E, Garcia-Vello P, Wool E. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet infectious diseases. 2025 Sep 1;25(9):1033-43.
29. Zhang C, Fu X, Liu Y, Zhao H, Wang G. Burden of infectious diseases and bacterial antimicrobial resistance in China: a systematic analysis for the global burden of disease study 2019. The Lancet Regional Health–Western Pacific. 2024 Feb 1;43.
30. Wise J. One in six bacterial infections worldwide are now resistant to antibiotics, WHO warns. BMJ: British Medical Journal (Online). 2025 Oct 14;391:r2165.
31. Zhang M, Tian Y, Gao B, Qin X, Shen Q, Li Z, Shi Y, Zhang L, Liu Y, Sun W, Mao L. Interpretation of the Global Tuberculosis Report 2025: Global epidemic trends and China's control strategy. Zoonoses. 2026 Mar 18;6(1):994.
32. Mapipa Q, Digban TO, Nnolim NE, Nwodo UU. Antibiogram profile and virulence signatures of Pseudomonas aeruginosa isolates recovered from selected agrestic hospital effluents. Scientific Reports. 2021 Jun 3;11(1):11800.
33. Vasala A, Hytönen VP, Laitinen OH. Modern tools for rapid diagnostics of antimicrobial resistance. Frontiers in cellular and infection microbiology. 2020 Jul 15;10:308.
34. Sinha S, Upadhyay LS. Understanding antimicrobial resistance (AMR) mechanisms and advancements in AMR diagnostics. Diagnostic microbiology and infectious disease. 2025 Oct 1;113(2):116949.

ISSN (O): 2687-5365; ISSN (P): 2753-6556

35. Ranjalkar J, Chandy SJ. India's National Action Plan for antimicrobial resistance–An overview of the context, status, and way ahead. Journal of family medicine and primary care. 2019 Jun;8(6):1828.
36. Simon UK. An instant update on viruses. The American Biology Teacher. 2021 Mar 1;83(3):147-53.
37. Huang J, Song Q, Zhang P, Deng L, Gao F, Deng Y, Krol E, Růžek D, Khouri R, De Clercq E, Li G. AntiviralDB: an expert-curated database of antiviral agents against human infectious diseases. MBio. 2025 Oct 8;16(10):e02013-25.
38. Simon UK. An instant update on viruses. The American Biology Teacher. 2021 Mar 1;83(3):147-53.
39. Moelling K, Broecker F. Viruses and evolution–viruses first? A personal perspective. Frontiers in microbiology. 2019 Mar 19;10:523.
40. Côrtes N, Lira A, Prates-Syed W, Dinis Silva J, Vuitika L, Cabral-Miranda W, Durães-Carvalho R, Balan A, Cabral-Marques O, Cabral-Miranda G. Integrated control strategies for dengue, Zika, and Chikungunya virus infections. Frontiers in immunology. 2023 Dec 18;14:1281667.
41. Shen-Gunther J, Easley A. HPV, HBV, and HIV-1 viral integration site mapping: A streamlined workflow from NGS to genomic insights of carcinogenesis. Viruses. 2024 Jun 18;16(6):975.
42. Alanazi A, Ibrahim MN, El Azab EF, Elithy MA. Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets. Viruses. 2026 Jan 18;18(1):125.
43. Rehman SU, Shafique L, Ihsan A, Liu Q. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. Pathogens. 2020 Mar 23;9(3):240.
44. Katsarou K, Bardani E, Kallemi P, Kalantidis K. Viral detection: past, present, and future. Bioessays. 2019 Oct;41(10):1900049.
45. Ohst C, Saschenbrecker S, Stiba K, Steinhagen K, Probst C, Radzimski C, Lattwein E, Komorowski L, Stöcker W, Schlumberger W. Reliable serological testing for the diagnosis of emerging infectious diseases. Dengue and zika: control and antiviral treatment strategies. 2018 May 30:19-43.
46. Kumar A, Saini S, Anvikar A, Mishra N, Misra G. Evolving landscape of emerging virus diagnosis: Challenges and innovations. Molecular Biotechnology. 2026 Feb;68(2):386-408.
47. Zhao J, Hou X, Chang G. Advances in rapid detection technologies for zoonotic diseases: a one health-oriented review. Frontiers in Cellular and Infection Microbiology. 2026 Jul 7;16:1791165.
48. Thambugala KM, Daranagama DA, Tennakoon DS, Jayatunga DP, Hongsanan S, Xie N. Humans vs. fungi: An overview of fungal pathogens against humans. Pathogens. 2024 May 17;13(5):426.
49. Friedman DZ, Schwartz IS. Emerging fungal infections: new patients, new patterns, and new pathogens. Journal of Fungi. 2019 Jul 20;5(3):67.
50. Brown GD, Ballou ER, Bates S, Bignell EM, Borman AM, Brand AC, Brown AJ, Coelho C, Cook PC, Farrer RA, Govender NP. The pathobiology of human fungal infections. Nature Reviews Microbiology. 2024 Nov;22(11):687-704.
51. Kontoyiannis DP, Walsh TJ. Mucormycosis. New England Journal of Medicine. 2026 Feb 12;394(7):684-98.
52. Fan F, Liu Y, Liu Y, Lv R, Sun W, Ding W, Cai Y, Li W, Liu X, Qu W. Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies. International journal of antimicrobial agents. 2022 Nov 1;60(5-6):106673.
53. Chen XF, Hou X, Xiao M, Zhang L, Cheng JW, Zhou ML, Huang JJ, Zhang JJ, Xu YC, Hsueh PR. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) analysis for the identification of pathogenic microorganisms: a review. Microorganisms. 2021 Jul 19;9(7):1536.
54. Chaudhari V, Vairagade V, Thakkar A, Shende H, Vora A. Nanotechnology-based fungal detection and treatment: current status and future perspective. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024 Jan;397(1):77-97.
55. Christaki E. Classification of parasitic diseases. InThe surgical management of parasitic diseases 2020 Jul 24 (pp. 23-45). Cham: Springer International Publishing.
56. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, Hay SI. Global epidemiology of Plasmodium vivax. The American journal of tropical medicine and hygiene. 2016 Dec 28;95(6 Suppl):15.
57. Jayakody N, Gordon CA, Wickramasinghe N, Silva A, Wickramasinghe S, Weerakoon K. Diagnostic accuracy of nucleic acid amplification tests for human intestinal nematode infections: A systematic review and meta-analysis. PLOS Neglected Tropical Diseases. 2026 Feb 11;20(2):e0013974.
58. Ramirez-Plascencia HH, Colima-Fausto AG, Licona-Lasteros KC, Díaz-Zaragoza M, Cazarez-Navarro G, Macias-Barragan JG, Rodriguez-Preciado SY. Presence of microorganisms in the environment: One Health approach. Microorganisms. 2025 Oct 23;13(11):2435.
59. Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of childhood malnutrition on host defense and infection. Clinical microbiology reviews. 2017 Oct;30(4):919-71.
60. Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes and infection. 2015 Mar 1;17(3):173-83.
61. Di Domenico EG, Oliva A, Guembe M. The current knowledge on the pathogenesis of tissue and medical device-related biofilm infections. Microorganisms. 2022 Jun 21;10(7):1259.
62. Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell death discovery. 2023 Dec 19;9(1):465.
63. Sumrall ET, Keller AP, Shen Y, Loessner MJ. Structure and function of Listeria teichoic acids and their implications. Molecular microbiology. 2020 Mar;113(3):627-37.
64. Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nature Reviews Microbiology. 2004 Sep 1;2(9):747-65.
65. Tripathi N, Zubair M, Sapra A. Gram staining. InStatPearls [Internet] 2025 Mar 28. StatPearls Publishing.
66. Weissferdt A. Infectious lung disease. InDiagnostic Thoracic Pathology 2020 Jul 7 (pp. 3-71). Cham: Springer International Publishing.
67. Clark AE, Kaleta EJ, Arora A, Wolk DM. Matrix-assisted laser desorption ionization–time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clinical microbiology reviews. 2013 Jul;26(3):547-603.
68. Marsit NM, Saadawi S, Alennabi K. Challenges of growth-based microbiological methods in sterility assurance of pharmaceutical product manufacturing. Discover Pharmaceutical Sciences. 2025 Aug 27;1(1):13.
69. Vashist SK, Luong JH. Handbook of immunoassay technologies. Enzyme-linked immunoassays. 2018 Jan 4.
70. Roy V, Fischinger S, Atyeo C, Slein M, Loos C, Balazs A, Luedemann C, Astudillo MG, Yang D, Wesemann DR, Charles R. SARS-CoV-2-specific ELISA development. Journal of immunological methods. 2020 Sep 1;484:112832.
71. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. The Lancet infectious diseases. 2004 Jun 1;4(6):337-48.
72. Kim H, Huh HJ, Park E, Chung DR, Kang M. Multiplex molecular point-of-care test for syndromic infectious diseases. BioChip Journal. 2021 Mar;15(1):14-22.
73. Alatawi AD, Hetta HF, Ali MA, Ramadan YN, Alaqyli AB, Alansari WK, Aldhaheri NH, Bin Selim TA, Merdad SA, Alharbi MO, Alatawi WA. Diagnostic innovations to combat antibiotic resistance in critical care: tools for targeted therapy and stewardship. Diagnostics. 2025 Sep 5;15(17):2244.
74. Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annual

ISSN (O): 2687-5365; ISSN (P): 2753-6556

review of pathology: mechanisms of disease. 2019 Jan 24;14(1):319-38.
75. Bryant J, Chewapreecha C, Bentley SD. Developing insights into the mechanisms of evolution of bacterial pathogens from whole-genome sequences. Future microbiology. 2012 Nov 1;7(11):1283-96.
76. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA. Antimicrobial resistance: a growing serious threat for global public health. InHealthcare 2023 Jul 5 (Vol. 11, No. 13, p. 1946). MDPI.
77. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clinical microbiology reviews. 2018 Oct;31(4):10-128.
78. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS microbiology. 2018 Jun 26;4(3):482.
79. Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nature Reviews Microbiology. 2024 Oct;22(10):598-616.
80. Al-Khalaifah H, Rahman MH, Al-Surrayai T, Al-Dhumair A, Al-Hasan M. A One-Health perspective of antimicrobial resistance (AMR): human, animals and environmental health. Life. 2025 Oct 13;15(10):1598.
81. Majumder MA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infection and drug resistance. 2020 Dec 29:4713-38.
82. Alatawi AD, Hetta HF, Ali MA, Ramadan YN, Alaqyli AB, Alansari WK, Aldhaheri NH, Bin Selim TA, Merdad SA, Alharbi MO, Alatawi WA. Diagnostic innovations to combat antibiotic resistance in critical care: tools for targeted therapy and stewardship. Diagnostics. 2025 Sep 5;15(17):2244.
83. Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial stewardship: how the microbiology laboratory can right the ship. Clinical microbiology reviews. 2017 Jan;30(1):381-407.
84. De Gaetano S, Ponzo E, Midiri A, Mancuso G, Filippone D, Infortuna G, Zummo S, Biondo C. Global trends and action items for the prevention and control of emerging and re-emerging infectious diseases. Hygiene. 2025 May 2;5(2):18.
85. Jones BA, Grace D, Kock R, Alonso S, Rushton J, Said MY, McKeever D, Mutua F, Young J, McDermott J, Pfeiffer DU. Zoonosis emergence linked to agricultural intensification and environmental change. Proceedings of the national academy of sciences. 2013 May 21;110(21):8399-404.
86. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, Wesolowski A. Infectious disease in an era of global change. Nature reviews microbiology. 2022 Apr;20(4):193-205.
87. Buchan BW, Ledeboer NA. Emerging technologies for the clinical microbiology laboratory. Clinical microbiology reviews. 2014 Oct;27(4):783-822.
88. Liu K, Li P, Fang LQ, Liu W. Geospatial epidemiological approaches to the prevention and control of vector-borne diseases: A systematic review. Infectious Diseases & Immunity. 2026 Jan 20;6(01):37-47.
89. Little SE, Bowman DD. Vector-borne diseases. Georgis' Parasitology for Veterinarians-E-Book: Georgis' Parasitology for Veterinarians-E-Book. 2013 Nov 15;241.
90. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, Tenover FC, Alland D, Blaschke AJ, Bonomo RA, Carroll KC. Better tests, better care: improved diagnostics for infectious diseases. Clinical Infectious Diseases. 2013 Dec 1;57(suppl_3):S139-70.
91. Haque M, Sartelli M, McKimm J, Bakar MA. Health care-associated infections–an overview. Infection and drug resistance. 2018 Nov 11:2321-33.
92. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clinical microbiology reviews. 2005 Oct;18(4):638-56.
93. Manning ML, Septimus EJ, Ashley ES, Cosgrove SE, Fakih MG, Schweon SJ, Myers FE, Moody JA. Antimicrobial stewardship and infection prevention—leveraging the synergy: a position paper update. infection control & hospital epidemiology. 2018 Apr;39(4):467-72.
94. World Health Organization. Global report on infection prevention and control. World Health Organization; 2022 May 23.
95. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings [Internet]. 2019 May.
96. Kozel TR, Burnham-Marusich AR. Point-of-care testing for infectious diseases: past, present, and future. Journal of clinical microbiology. 2017 Aug;55(8):2313-20.
97. Zargul A, Liu H, Zhang W, Wang H, Liu J, Chen C. Advances in pathogen detection by nanosensors: biorecognition strategies, signal amplification, and platform engineering. ACS nano. 2026 Mar 11;20(11):9007-50.
98. Chakraborty S. Democratizing nucleic acid-based molecular diagnostic tests for infectious diseases at resource-limited settings–from point of care to extreme point of care. Sensors & Diagnostics. 2024 Apr 1;3(4):536-61.
99. Miglietta L, Rawson TM, Galiwango R, Tasker A, Ming DK, Akogo D, Ferreyra C, Aboagye EO, Gordon NC, Garcia-Vidal C, Rodriguez-Manzano J. Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives. The Lancet Infectious Diseases. 2025 Sep 16.
100. Pennisi F, Pinto A, Ricciardi GE, Signorelli C, Gianfredi V. The role of artificial intelligence and machine learning models in antimicrobial stewardship in public health: a narrative review. Antibiotics. 2025 Jan 30;14(2):134.
101. Chinta SV, Wang Z, Palikhe A, Zhang X, Kashif A, Smith MA, Liu J, Zhang W. AI-driven healthcare: A review on ensuring fairness and mitigating bias. PLOS Digital Health. 2025 May 20;4(5):e0000864.

ISSN (O): 2687-5365; ISSN (P): 2753-6556